3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
9
Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Pancreatic Neoplasms
6
Colorectal Neoplasms
5
Lymphoma
4
Liver Neoplasms
4
Lung Neoplasms
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Nasopharyngeal Carcinoma
2
Multiple Myeloma
2
Mesothelioma
2
Locally Advanced Rectal Cancer
2
Hematologic Diseases
2
Esophageal Squamous Cell Carcinoma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Adenocarcinoma
2
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Interventions
Ipilimumab
12
tremelimumab
6
durvalumab
6
Nivolumab
6
pembrolizumab
4
Paclitaxel
2
Oxaliplatin
2
Carboplatin
2
Capecitabine
2
Blood Specimen Collection
2
spartalizumab
1
relatlimab
1
lenvatinib
1
folfirinox
1
Vaccines
1
Radiotherapy
1
Radiofrequency Ablation
1
Radiation
1
Opdualag
1
Monophenol Monooxygenase
1
Leucovorin
1
Fluorouracil
1
Docetaxel
1
Cryosurgery
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Diabetes Mellitus, Insulin-Dependent, 12
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts